What Clinicians Should Know About Hypertension Management
Hypertension remains one of the leading modifiable risk factors for cardiovascular disease worldwide. While orthodox medications remain the mainstay of treatment, growing interest in cannabinoid medicine has led researchers to explore whether cannabidiol (CBD) may also have a role in blood pressure regulation.
A newly published systematic review of randomized controlled trials evaluated the effects of oral CBD in both healthy adults and individuals with hypertension. Across the four clinical trials included (120 participants), oral CBD was associated with statistically significant reductions in systolic blood pressure compared with placebo, particularly during stress and sleep. Greater reductions were generally observed with higher daily doses (225–600 mg/day), while reported side effects—including fatigue, nausea, and diarrhea—were generally mild to moderate.
Why This Matters
Although the findings are encouraging, interpret them in the context of the available evidence. The studies were relatively small, varied considerably in dose, duration, and formulation, and evaluated oral CBD at doses substantially higher than those found in many commercially available products.
Rather than suggesting CBD should replace established antihypertensive therapies, the results support the growing view that cannabinoid-based medicines may eventually become one component of a more individualized cardiovascular care strategy for selected patients.
Clinical Perspective
Mechanistically, the findings are biologically plausible. CBD has been shown to influence stress responses, inflammation, vascular function, and autonomic regulation—all factors that contribute to blood pressure control. At the same time, clinicians should remain mindful of potential medication interactions, variability in individual response, and the need for longer-term studies before recommending routine clinical use.
Questions Worth Asking
As cannabinoid medicine keeps on evolving, several practical questions emerge:
- Which patient populations are most likely to benefit?
- What dose and formulation best balance efficacy and tolerability?
- How should CBD be integrated alongside existing antihypertensive therapies?
- Which medications or comorbidities warrant additional caution?
Looking Forward
At CannaKeys, our goal is not simply to summarize new studies but to place emerging evidence into its greater clinical context. As additional cardiovascular research becomes available, we’ll continue updating our evidence reviews, clinical considerations, and treatment plans to help members translate new research into informed clinical decision-making.
Roberts A, Fountzopoulos S, Desai T. The effects of oral cannabidiol supplementation on blood pressure in adults: a systematic review of randomised controlled trials. J Cannabis Res. 2026 Jun 19. doi: 10.1186/s42238-026-00463-3. Epub ahead of print. PMID: 42321899. https://pmc.ncbi.nlm.nih.gov/articles/PMC13531894/
